A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin , Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease
Interventional
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Progression-free survival (defined as the time from randomization to the first occurrence of progression based on RECIST 1.1 criteria or death from any cause on study)
Up to 24 months
No
Ina Rhee, M.D., Ph.D.
Study Director
Genentech
United States: Food and Drug Administration
MEF4984g
NCT01366131
June 2011
June 2014
Name | Location |
---|---|
Alexandria, Minnesota 56308 | |
Albany, Georgia 31701 | |
Birmingham, Alabama 35294 | |
Fountain Valley, California 92708 | |
Miami, Florida 33176 | |
Albany, New York 12208 | |
Cleveland, Ohio 44195 | |
Philadelphia, Pennsylvania 19104 | |
Nashville, Tennessee 37203-1632 | |
Austin, Texas 78705 | |
Seattle, Washington 98195 | |
Little Rock, Arkansas 72205-7199 | |
Kansas City, Kansas 66160 | |
Eugene, Oregon | |
Indianapolis, Indiana | |
Las Vegas, Nevada 89109 |